Insight2022-03-31T12:20:53+01:00
Loading...

Latest news and thought leadership

All the latest from Deallus pharmaceutical and life science industry experts

Deallus welcomes George Gu, Principal & Head of China, Shanghai

April 21st, 2022|Categories: News|

Deallus is delighted to announce that George Gu joined our team on the 6th of April. Medical Doctor by training - focusing on Radiation Oncology - George has spent the last 7 years working with various consulting and start-up companies, gaining valuable experience in medical internet and genomic profiling companies.

Deallus welcomes Kunal Kaushal Principal, New York

April 7th, 2022|Categories: News|

Deallus welcomes Kunal Kaushal as a Principal in the New York office. Kunal brings more than 14 years of strategy consulting and advisory experience to the role, his expertise spanning many different project types, geographies, and therapeutic areas. His TA focus includes Oncology, Cardiovascular, Gastrointestinal, Anti-Obesity and Rheumatology.

CARe To Understand What Will Shape CAR T’s Future?

March 16th, 2021|Categories: Thought Piece, White Paper|Tags: , , |

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

OnDemand Webinar – Leading in a crisis

February 2nd, 2021|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.

Kevin Bibby joins Deallus as Senior Principal

January 5th, 2021|Categories: News|

We are very pleased to welcome Kevin Bibby to our Deallus team as Senior Principal. Kevin brings extensive expertise in commercial strategy to the fold, as well as a deep background in brand and portfolio strategy, product positioning, and workshop facilitation. We look forward to adding his knowledge, skill sets, and collaborative spirit to the team.

Disruption has hit pharma

Strategic intelligence for a fiercely competitive marketplace. In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. Deallus look at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.

CARe To Understand What Will Shape CAR T’s Future?

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

March 16th, 2021|Categories: Thought Piece, White Paper|Tags: , , |

The Future of JAK Inhibitors

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. Yet despite the hurdles, JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted. Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option? In this white paper, we investigate the current state of JAKs and explore their likelihood of success in the future.

January 6th, 2020|Categories: White Paper|Tags: , , |

OnDemand Webinar – Leading in a crisis

February 2nd, 2021|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.

OnDemand Webinar – Navigating Market Disruption after COVID-19

September 3rd, 2020|Categories: News, Thought Piece, Video|Tags: , |

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

Competitive Simulation Strategy

Tags: , , , |

Our client was facing a major pharma player in a highly lucrative and rare disease space. They wanted to ensure that they had a chance to analyze their competition’s launch plan and plans for targeting their own product, but they did not have the time to conduct a cross-functional, traditional workshop. They came to us to discuss their goals and assess the most strategic way forward. This case study explores this launch scenario in which we put a unique spin on the traditional competitive simulation approach for our client.

Launching for Success

Tags: , , , |

Our client was a small-to medium-sized pharmaceutical company with a limited development pipeline who was in the process of launching their first product, an orphan drug, for treating a rare disease. They were a relatively small organisation with no prior knowledge of the competitive environment and no standardised launch planning process or procedures. This case study explores how our client engaged us to help them understand their competitive landscape, streamline launch efforts across markets, and stress test and revise their launch planning strategies.

Asset Evaluation

Tags: , , , , |

Our client was a medium-sized pharma company interested in launching an antibiotic asset for treating pathogens with limited treatment options in Central and Southern Europe, as well as the Middle East. Their antibiotic was a particularly strong candidate for commercialization due to its novelty in tackling multi-resistant antibiotic pathogens and the extremely high unmet demands in the targeted regions. Our client engaged us to work with their business intelligence managers in order to evaluate the commercial value of the asset and to advise on the best strategic route to commercialization.

Pharma CI US 2020

Sponsors at Pharma CI US

Sept 29 – Oct 1, 2020
VIRTUAL EVENT

Learn more
PharmaCI Europe 2020

Sponsors at PharmaCI Europe

July 1-2, 2021
Zurich, Switzerland

Learn more

Register your email address to be alerted to our latest news

    Go to Top